Enrollment Complete in Acorda's MS Trial

Acorda Therapeutics has completed enrollment for its Phase III trial of Fampridine-SR in multiple sclerosis (MS) patients.

The 240-patient trial is designed to evaluate Fampridine-SR in improving walking ability in people with MS.

Acorda said it expects data from the trial in the second quarter of 2008.